Nurix Therapeutics (NRIX) Stock Looks Pricey After Roche Deal And Weaker Quarter

Nurix Therapeutics (NRIX) has drawn fresh attention after reporting second quarter 2026 results alongside a new global partnership with Roche for its BTK degrader bexobrutideg, combining scientific ambitions with changing financial signals.

See our latest analysis for Nurix Therapeutics.

Nurix Therapeutics’ share price has been volatile around the latest quarter, with the stock down 6.6% on the day and 3.8% over the past week, but still showing a 50.7% 1 month share price return and an 85.4% 1 year total shareholder return. This suggests recent momentum has followed a much longer build up in investor interest despite wider losses.

If Nurix’s partnership news has you thinking more broadly about biotech opportunities, this could be a good moment to scan other healthcare-focused AI plays using the 41 healthcare AI stocks

After such a sharp swing in Nurix Therapeutics on the back of weaker earnings but a large Roche deal, the real tension now is simple: does the current price still leave enough upside to justify the biotech risk?

Price-to-Sales of 33.3x: Is it justified?

With Nurix Therapeutics last closing at $23.06, the current valuation implies a P/S ratio of 33.3x, which is high relative to peers despite strong forecast revenue growth.

The P/S ratio compares the company’s market value to its revenue and is often used for biotechs that are still loss making and do not yet have meaningful earnings. For Nurix Therapeutics, this means investors are paying a sizeable multiple of current sales while the company remains unprofitable and is forecast to stay in the red over the next 3 years.

Against that backdrop, the current 33.3x P/S looks rich compared to the US Biotechs industry average of 12x and the estimated fair P/S of 0.1x. The market is assigning a much higher valuation than both the industry reference point and the level suggested by the fair ratio model. This represents a wide gap for investors to weigh when judging how much future revenue growth is already built into the price.

Explore the SWS fair ratio for Nurix Therapeutics

Result: Price-to-Sales of 33.3x (OVERVALUED)

However, Nurix Therapeutics still faces clinical and partnership risks, as trial setbacks or changes in collaboration terms could quickly shift sentiment around the current valuation.

Find out about the key risks to this Nurix Therapeutics narrative.

Next Steps

If you are unsure whether Nurix Therapeutics’ risk and reward signals align with your comfort level, now may be a useful time to review the data and form your own view by examining the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Nurix Therapeutics?

If Nurix Therapeutics has sharpened your focus on where capital goes next, do not sit on the sidelines when there are curated stock ideas waiting for you.

• Target resilient opportunities with 76 resilient stocks with low risk scores that prioritise steadier profiles for investors who want fewer surprises when markets get choppy.
• Hunt for potential bargains using the 44 high quality undervalued stocks that highlight companies trading below what their fundamentals might justify.
• Spot overlooked potential through the screener containing 19 high quality undiscovered gems that surface smaller, less followed stocks many investors have not considered yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com